Alzamend Neuro

ALZN · NASDAQ

$1.30−$0.03 (−2.26%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.33

ALZN analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $26.52 (+1940.0% upside)

Low: $26.26
Now: $1.30
High: $27.30

Upgrades and downgrades

The latest rating actions, newest first

ALZN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Aug 19, 2026	Maintains	Buy	$25.00 → $26.00	28%
Ascendiant Capital	Dec 22, 2025	Maintains	Buy	$42.00 → $28.00	28%

The case for and against

Updated Mar 13, 2026

Bull case

Alzamend Neuro Inc., an early clinical-stage biopharmaceutical company, is dedicated to developing innovative treatments for neurodegenerative diseases and psychiatric disorders, with a strong focus on its promising pipeline candidates AL001 and AL002. The company has recently reported positive top-line results from its studies, which are expected to serve as significant catalysts for future stock performance. Additionally, the current valuation is viewed as attractive, with substantial upside potential identified through a net present value analysis, reflecting a favorable outlook for the company's financial growth.

Bear case

Alzamend Neuro Inc reported a net loss of $2.7 million, resulting in an earnings per share (EPS) of $(1.28), significantly worse than the estimated EPS of $(0.69). The company faces multiple risks that could hinder its financial performance, including liquidity challenges and the potential failure of its drug candidates to prove safety and efficacy during clinical trials. Additionally, the competitive landscape and obstacles in commercialization and regulatory approval could further complicate the company’s ability to secure reimbursement and market its products effectively.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.